B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PRKACB

MOLECULAR TARGET

protein kinase cAMP-activated catalytic subunit beta

UniProt: P22694NCBI Gene: 556715 compounds

PRKACB (protein kinase cAMP-activated catalytic subunit beta) is targeted by 15 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PRKACB

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1midostaurin3.8546
2sb 2021903.6437
3tae 6843.4330
4at 92833.0921
5lestaurtinib3.0420
6pf 037583093.0019
7ruboxistaurin2.9418
8r 4062.8316
9capivasertib2.7715
10gsk 6906932.6413
11ast 4872.5612
12enzastaurin2.087
13uprosertib1.956
14afuresertib1.795
15hydroxyfasudil [Supplementary Concept]1.393

About PRKACB as a Drug Target

PRKACB (protein kinase cAMP-activated catalytic subunit beta) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 15 compounds with documented PRKACB interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PRKACB inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.